middle.news
Mesoblast Secures Exclusive CAR Technology to Boost Cell Therapy Precision
9:34am on Wednesday 15th of April, 2026 AEST
•
Healthcare
Read Story
Mesoblast Secures Exclusive CAR Technology to Boost Cell Therapy Precision
9:34am on Wednesday 15th of April, 2026 AEST
Key Points
Exclusive worldwide license to CAR technology from Mayo Clinic
CAR-engineered MSCs to improve targeting and immunomodulation
Immediate applications in ulcerative colitis, Crohn's disease, and lupus nephritis
Acquisition completed via ASX share issuance with Mayo Clinic support
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE